These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33206322)

  • 21. Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Copertino DC; Duarte RRR; Powell TR; de Mulder Rougvie M; Nixon DF
    J Med Virol; 2021 Jan; 93(1):187-189. PubMed ID: 32658304
    [No Abstract]   [Full Text] [Related]  

  • 22. A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2.
    Das M; Kumar M; Jha A; Madhukiran DR; Bharti K; Mondal S; Mishra B
    Curr Drug Targets; 2021; 22(11):1232-1254. PubMed ID: 33371846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An EUA for bamlanivimab and etesevimab for COVID-19.
    Med Lett Drugs Ther; 2021 Apr; 63(1621):49-50. PubMed ID: 33830966
    [No Abstract]   [Full Text] [Related]  

  • 24. SARS-CoV-2 Variants in Patients with Immunosuppression.
    Corey L; Beyrer C; Cohen MS; Michael NL; Bedford T; Rolland M
    N Engl J Med; 2021 Aug; 385(6):562-566. PubMed ID: 34347959
    [No Abstract]   [Full Text] [Related]  

  • 25. Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.
    Paul SS; Biswas G
    Mini Rev Med Chem; 2021; 21(9):1123-1143. PubMed ID: 33355053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcription-based drug repurposing for COVID-19.
    Killick R; Ballard C; Doherty P; Williams G
    Virus Res; 2020 Dec; 290():198176. PubMed ID: 32987033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches.
    Raj V; Park JG; Cho KH; Choi P; Kim T; Ham J; Lee J
    Int J Biol Macromol; 2021 Jan; 168():474-485. PubMed ID: 33290767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 Updates: Monoclonal Antibodies for COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286
    [No Abstract]   [Full Text] [Related]  

  • 29. Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit.
    Hall MD; Anderson JM; Anderson A; Baker D; Bradner J; Brimacombe KR; Campbell EA; Corbett KS; Carter K; Cherry S; Chiang L; Cihlar T; de Wit E; Denison M; Disney M; Fletcher CV; Ford-Scheimer SL; Götte M; Grossman AC; Hayden FG; Hazuda DJ; Lanteri CA; Marston H; Mesecar AD; Moore S; Nwankwo JO; O'Rear J; Painter G; Singh Saikatendu K; Schiffer CA; Sheahan TP; Shi PY; Smyth HD; Sofia MJ; Weetall M; Weller SK; Whitley R; Fauci AS; Austin CP; Collins FS; Conley AJ; Davis MI
    J Infect Dis; 2021 Jul; 224(Supplement_1):S1-S21. PubMed ID: 34111271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ensuring continued progress for development of COVID-19 therapeutics in children.
    Noel GJ; DeBiasi RL; Crandall W; Connor EM
    Pediatr Res; 2021 Dec; 90(6):1112-1114. PubMed ID: 33603214
    [No Abstract]   [Full Text] [Related]  

  • 31. Antivirals for Coexistence with COVID-19: Brief Review for General Physicians.
    Yoo JH
    J Korean Med Sci; 2021 Nov; 36(42):e298. PubMed ID: 34725982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.
    Colson P; La Scola B; Lagier JC; Gautret P; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106238. PubMed ID: 33408030
    [No Abstract]   [Full Text] [Related]  

  • 33. COVID-19: morphology and mechanism of the SARS-CoV-2, global outbreak, medication, vaccines and future of the virus.
    Bhattacharyya P; Das S; Aich S; Sarkar J
    Front Biosci (Elite Ed); 2021 Dec; 13(2):272-290. PubMed ID: 34937314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phytochemicals for the treatment of COVID-19.
    Españo E; Kim J; Lee K; Kim JK
    J Microbiol; 2021 Nov; 59(11):959-977. PubMed ID: 34724178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lethal mutagenesis as an antiviral strategy.
    Swanstrom R; Schinazi RF
    Science; 2022 Feb; 375(6580):497-498. PubMed ID: 35113690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD147 inhibitors as a treatment for melanoma: Promising agents against SARS-CoV-2 infection.
    Pourani MR; Nekooghadam SM; Youssefian L; Vahidnezhad H; Abdollahimajd F
    Dermatol Ther; 2020 Nov; 33(6):e14449. PubMed ID: 33098610
    [No Abstract]   [Full Text] [Related]  

  • 37. Flexibility and mobility of SARS-CoV-2-related protein structures.
    Römer RA; Römer NS; Wallis AK
    Sci Rep; 2021 Feb; 11(1):4257. PubMed ID: 33608565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances Toward COVID-19 Therapies Special Issue.
    Neamati N
    J Med Chem; 2022 Feb; 65(4):2713-2715. PubMed ID: 35138859
    [No Abstract]   [Full Text] [Related]  

  • 39. Cutaneous lesions and COVID-19: Cystic painful lesion in a case with positive SARS-CoV-2.
    Goudarzi S; Dehghani Firouzabadi F; Dehghani Firouzabadi M; Rezaei N
    Dermatol Ther; 2020 Nov; 33(6):e14266. PubMed ID: 32882081
    [No Abstract]   [Full Text] [Related]  

  • 40. Alkaloids: Therapeutic Potential against Human Coronaviruses.
    Fielding BC; da Silva Maia Bezerra Filho C; Ismail NSM; Sousa DP
    Molecules; 2020 Nov; 25(23):. PubMed ID: 33255253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.